Home / Topics

Regulatory CMC

Regulatory Submissions & Lifecycle Management

A practical overview of how to assess post-approval CMC changes, track recurring filing obligations, and document manufacturing or analytical transfers.

This guide focuses on approved US NDAs and ANDAs and EU marketing authorisations for human medicines. For investigational products, check the applicable IND or clinical trial application procedures.

In this guide
  1. Post-approval CMC changes
  2. Annual and periodic reporting
  3. Technical transfer documentation

Post-approval CMC changes in the US and EU

Start with the approved dossier for each affected market. Describe what will change, identify the relevant commitments, and assess the potential impact on product quality before selecting a filing route or setting a distribution date.

United States

Under 21 CFR 314.70, major changes generally require FDA approval of a Prior Approval Supplement (PAS) before distribution. Moderate changes generally use a Changes Being Effected supplement, often CBE-30, with distribution upon receipt permitted in specified cases. Minor changes generally go in the annual report. Check the specific change, any applicable FDA guidance, and the approved application. 21 CFR 314.70.

European Union

Type IA covers minor changes with minimal or no impact, subject to the conditions in the classification guidelines. Eligible IA changes can be included in an annual update, while IAIN changes require immediate notification after implementation. Type IB typically requires notification and a waiting period before implementation. Type II covers major variations requiring prior approval. Use the applicable procedure and classification entry for the product. The revised EU Variations Guidelines apply from 15 January 2026. EMA guidance on the revised variations framework.

Annual reports and periodic safety or quality updates

Maintain a filing calendar by product and market. For US NDA and ANDA annual reports, check the applicable reporting period and reconcile reportable CMC changes with change controls and dossier records. EU Type IA annual updates follow the variations framework. Periodic safety update reports (PSURs) have their own obligations and schedules, including the EU reference dates (EURD) list where applicable. Track internal product quality reviews and stability commitments alongside filing obligations so each has an owner and due date. 21 CFR 314.81 and EMA guidance on PSURs.

A useful tracker records the approved baseline, change-control ID, affected products and markets, filing route, timing, evidence links, authority status and any follow-up commitments. Reconcile the tracker against the dossier and site records before closing the change.

Technical transfer documentation

For an analytical method transfer, document the sending and receiving laboratories, approved method version, sample and standard selection, acceptance criteria, deviations and final transfer conclusion. For a manufacturing transfer, assess the receiving site's equipment, process controls and validation needs, and justify any batch comparability and stability evidence.

Where appropriate, prospectively define the proposed change, studies, acceptance criteria and follow-up in a regulatory comparability protocol or post-approval change management protocol (PACMP). Confirm the regional filing steps and the conditions under which the protocol can be used. FDA comparability protocol guidance and ICH Q12.

For example, if a proposed packaging site transfer also changes the container closure, record both changes and assess their combined effect. Link the change control to the affected Module 3 sections, the data supporting the change and the market-specific implementation decision. See the CTD Module 3 guide.